济川药业(600566) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was CNY 1,525,389,316.30, a decrease of 36.51% compared to the same period last year[4] - Net profit attributable to shareholders was CNY 440,335,904.83, down 47.91% year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 392,137,823.14, a decline of 46.01% compared to the previous year[4] - The net cash flow from operating activities was CNY 793,904,475.78, representing a decrease of 40.70% year-on-year[4] - Basic earnings per share were CNY 0.48, down 47.83% from CNY 0.92 in the same period last year[4] - The company's net profit for Q1 2025 was RMB 419,297,717.76, compared to RMB 808,269,636.78 in Q1 2024, reflecting a decline of 48.2%[19] - The total profit for Q1 2025 was CNY 514.67 million, down 48.0% from CNY 989.79 million in Q1 2024[21] Revenue and Costs - The total operating revenue for Q1 2025 was RMB 1,525,389,316.30, a decrease of 36.4% compared to RMB 2,402,545,954.32 in Q1 2024[19] - The total operating costs for Q1 2025 were RMB 1,106,091,598.54, down 30.6% from RMB 1,594,276,317.54 in Q1 2024[19] - The gross profit margin for Q1 2025 was approximately 27.5%, compared to 37.0% in Q1 2024[19] - The decline in revenue and profit was primarily due to reduced sales of major products and an increase in cost expense ratio[7] Assets and Liabilities - Total assets at the end of the reporting period were CNY 18,333,497,578.36, a decrease of 0.68% from the end of the previous year[5] - The total assets as of March 31, 2025, were RMB 18,333,497,578.36, a slight decrease from RMB 18,459,493,906.46 at the end of 2024[18] - The total liabilities decreased to RMB 3,166,200,048.41 as of March 31, 2025, from RMB 3,733,067,567.74 at the end of 2024, indicating a reduction of 15.2%[17] Shareholder Equity - Shareholders' equity attributable to shareholders was CNY 15,141,767,178.40, an increase of 2.99% compared to the end of the previous year[5] - The weighted average return on equity decreased by 3.19 percentage points to 2.95%[4] Cash Flow - The cash and cash equivalents increased to RMB 7,415,120,901.39 as of March 31, 2025, up from RMB 6,669,362,743.71 at the end of 2024, representing a growth of 11.2%[15] - The cash inflow from investment activities was CNY 917.85 million, significantly lower than CNY 2.12 billion in Q1 2024[24] - The company reported a net cash outflow from investing activities of CNY 9.20 million, contrasting with a net inflow of CNY 1.66 billion in Q1 2024[24] - The company reported a cash outflow from financing activities of CNY 322.58 million, compared to CNY 15.63 million in Q1 2024[24] Share Repurchase - The company has repurchased a total of 220,500 shares, accounting for 0.02% of the total share capital, with a total expenditure of RMB 6,099,831 as of March 31, 2025[13] - The company plans to continue share repurchase activities within the approved budget of RMB 2,500,000 to RMB 5,000,000, with a maximum repurchase price of RMB 48 per share[13] Expenses - The company reported a significant reduction in sales expenses, which were RMB 557,671,736.88 in Q1 2025, down from RMB 989,645,386.93 in Q1 2024, a decrease of 43.7%[19] - The company incurred credit impairment losses of CNY 37.36 million in Q1 2025, compared to CNY 41.48 million in Q1 2024[20]